Assessing a European in-licensing opportunity in chemotherapy-induced diarrhoea

Our mid-sized pharma client was considering in-licensing a new product for chemotherapy-induced diarrhoea.

They sought to challenge the vendor’s assessment of the product’s commercial potential in Europe.

Through focused research – including payer insights, treatment guidelines, and pricing and treatment cost dynamics – we created a sales forecast model in just weeks to support our client in achieving the best deal.

The challenge

Assessing commercial forecasts and access hurdles across major European markets for an orphan product in-licensing opportunity in chemotherapy-induced diarrhoea.

How we helped

We developed a detailed understanding of the likely access hurdles and challenges facing the product by reviewing the pricing and reimbursement status of alternative therapies and targeted payer and KOL interviews.

Our team created a commercial forecast model based on these insights, and on our knowledge of product funding routes, national and regional reimbursement pathways and local formulary access across the European markets in question.

Outcome

This work positioned our client to challenge, using robust evidence, the vendor's assessment of the product's commercial potential. This led to better deal-terms.